AFMD Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe...

Stats
Today's Volume	63 710.00
Average Volume	92 375.00
Market Cap	78.42M
EPS	€0 ( 2024-03-28 )
Next earnings date	( €-1.860 ) 2024-05-28
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.680
ATR14	€0.0480 (0.93%)

Volume Correlation

Long: 0.02 (neutral)

Short: 0.36 (neutral)

Signal:(60.024) Neutral

Affimed NV Correlation

10 Most Positive Correlations
ADAP	0.95
TNON	0.947
ONCR	0.941
EDTK	0.938
SOPA	0.938
AIHS	0.937
SEED	0.936
GRNV	0.934
ONCS	0.934
EDAP	0.933

10 Most Negative Correlations
ADBE	-0.958
FTIV	-0.953
PTMN	-0.951
WDAY	-0.946
MURFU	-0.946
NEWT	-0.944
ATLCP	-0.943
AMWD	-0.942
TATT	-0.942
AGNCO	-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Affimed NV Correlation - Currency/Commodity

0.58
( weak )

0.35
( neutral )

0.00
( neutral )

0.47
( neutral )

-0.66
( moderate negative )

-0.33
( neutral )

Affimed NV Financials

Annual	2023
Revenue:	€8.28M
Gross Profit:	€8.28M (100.00 %)
EPS:	€0

Q4	2023
Revenue:	€413 000
Gross Profit:	€413 000 (100.00 %)
EPS:	€0

Q3	2023
Revenue:	€1.96M
Gross Profit:	€1.96M (100.00 %)
EPS:	€-0.160

Q2	2023
Revenue:	€1.39M
Gross Profit:	€1.39M (100.00 %)
EPS:	€-0.200

Financial Reports:

No articles found.

Affimed NV

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.